Keywords: Nomura, Second-quartr results preview, AstraZeneca, Sanoif-Aventis
Will corporate activity be spur growth? ask Nomura analysts in 2nd-qtr results preview
Article | 12 July 2010
Ahead of the second-quarter 2010 financial results announcements, analysts at Nomura have issued a brief review, noting that, with few blockbusters ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
